Please login to the form below

Not currently logged in
Email:
Password:

Astellas purchases OSI

Japanese company Astellas Pharma has announced that it has completed the acquisition of US biotech, OSI Pharmaceuticals

Japan's second largest pharma company, Astellas Pharma, has announced that it has completed the acquisition of US biotech OSI Pharmaceuticals through a short-form merger.

In the deal, valued at $4bn, each outstanding share of OSI common stock not purchased in Astellas' tender offer, or otherwise owned by Astellas, was converted into the right to receive the same amount of $57.50. This is 11 per cent more than a previously proposed $52 per share.

OSI is now a wholly-owned subsidiary of Astellas US Holdings, which is owned by Astellas Pharma. The acquisition marks the completion of a hostile takeover bid launched in March this year after Astellas originally initiated talks with OSI in early 2009 and adds cancer blockbuster, Tarceva (erlotinib) to Astellas' portfolio.

Masafumi Nogimori, president and CEO of Astellas, said: "This compelling transaction marks an important step forward for Astellas as the company works towards developing a world-class oncology platform."

OSI is a biotechnology company focused on the discovery, development and commercialisation of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity. Tarceva is the company's lead cancer drug, with several other drug prospects in the R&D pipeline.

The purchase of OSI will bolster Astellas' existing interests in urology and transplantation as its urinary drug, Flomax (tamsulosin), and transplant drug, Prograf (tacrolimus), recently lost patent protection in the US and face generic competition.

It also takes Astellas into the US market after its hostile bid for CV Therapeutics failed last year.

9th June 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...

Infographics